CION Ameerpet
Head, Neck & Upper GI Immunotherapy · Tobacco
Tobacco Use and Immunotherapy Response — What It Changes and What It Does Not
If you have smoked or chewed tobacco for years, the question underneath “does smoking affect immunotherapy response” is usually a quieter one: have I already spoilt my chances? The short answer is no. Tobacco history is not an eligibility test and it is not how an oncologist chooses treatment. What decides it is whether the cancer can still be controlled locally, the PD-L1 combined positive score used by NCCN and ESMO head and neck guidance, and how well you are. Most patients with these cancers are not candidates for immunotherapy at all — and that is true whatever your tobacco history.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- Most patients are not candidates — immunotherapy applies to a narrow group in head, neck and upper GI cancer, whatever your tobacco history.
- Tobacco is not an eligibility test — you will not be refused treatment for smoking or chewing. PD-L1, fitness and organ function decide it.
- Quitting still counts, mid-treatment — stopping at any point lowers second-cancer risk and makes a new symptom far easier to read.
- Chewing tobacco is a real evidence gap — no reliable data says gutka or khaini predicts response. Be wary of anyone who claims it does.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Answer this first
Does Smoking or Chewing Tobacco Affect How Well Immunotherapy Works?
Start here: most patients with head, neck and upper gastrointestinal cancers in India are not candidates for immunotherapy at all. Where it does apply, tobacco history does not decide the answer. It shifts the biology in lung cancer. In head and neck cancers the evidence is mixed, and smoking status is not used to choose treatment.
That eligibility sentence has to come first, because it is the part families are rarely told. Checkpoint-inhibitor immunotherapy is considered when a cancer has returned or spread and further surgery or radiation can no longer control it. If a local treatment can still clear the disease, that comes first. Only inside the narrow group where local treatment has run out does the tobacco question become worth asking — and there, the answer is not the one most people expect.
The idea that smokers respond better comes from lung cancer, where it is a real observation. Tobacco damages DNA, so smoking-related lung tumours tend to carry a heavier load of genetic changes, which gives the immune system more to recognise. That pattern has been described repeatedly in the non-small-cell lung cancer literature summarised by NCCN and ESMO. It is a biological observation, not an eligibility rule, and it has not carried across cleanly to the cancers on this page.
| Cancer | What a tobacco history appears to do | Is it used to decide treatment? |
|---|---|---|
| Non-small-cell lung cancer | Smoking-related tumours carry more genetic damage; checkpoint-inhibitor treatment has generally worked better in current and former smokers than in never-smokers | No. PD-L1 expression and tumour testing set the plan, not smoking status. |
| Head and neck squamous cell cancer (throat, larynx) | The lung-cancer pattern has not held consistently. HPV-negative tobacco-driven cancers and HPV-positive cancers are both considered on the same criteria | No. NCCN and ESMO head and neck guidance uses the PD-L1 combined positive score (CPS). |
| Oral cavity cancer (tongue, cheek, gum) | Driven mainly by smokeless tobacco in India. Whether that changes response has never been properly studied | No. Whether local treatment can still control the disease comes first, then CPS. |
| Oesophageal and stomach cancer | Tobacco and alcohol are established causes. No established link between smoking history and how well treatment works | No. PD-L1 (CPS) and, in some cases, mismatch-repair or MSI status. |
| Bladder and kidney cancer | Smoking is the largest modifiable risk factor for both, and immunotherapy sits further forward in these pathways than it does in oral cancer | No. Stage, what has already been tried, and organ function decide it. |
Nothing here is a recommendation to start, stop or change a treatment. Every decision described on this page belongs to your treating team, working from your reports and your examination.
In India, chewing is the bigger exposure
The Global Adult Tobacco Survey (GATS-2, 2016–17) found that 28.6% of Indian adults used tobacco in some form, and that smokeless use (21.4%) was roughly double smoking (10.7%). Almost every large immunotherapy trial in head and neck cancer, by contrast, was run in countries where smoking was the dominant exposure. That mismatch is the honest reason this page cannot give you a confident answer about gutka and khaini — and the reason we would rather say so than guess.
The question worth acting on
Does Quitting Now Help, Even After Treatment Has Started?
Yes. Quitting helps at any point, including after immunotherapy has started. Stopping is linked to fewer treatment complications, better healing and a lower risk of a second tobacco-related cancer. NCCN and WHO both recommend cessation from diagnosis rather than after treatment ends. It also makes a new cough easier for your team to interpret.
This is where the page changes from information you cannot act on to something you can. You cannot undo thirty years of khaini. You can change what happens from this week, and the gain is not theoretical.
- Fewer complications during treatment. Wound healing, mucosal healing and infection risk all improve after stopping, which matters if surgery or radiation is still on your pathway.
- A lower risk of a second, separate cancer. This is the most consistent finding in cessation guidance, and it applies to people already being treated.
- Cleaner signals for your team. A smoker's cough hides an immune lung reaction. Take the cough away and a new one means something.
- Better day-to-day breathing and eating. Taste, appetite and breathlessness often improve within weeks, which matters when weight loss is already a problem.
- It is never framed as a condition of treatment. Support is offered because it helps you, not to earn access to a drug.
There is no honest claim to be made here about how long anyone lives, and this page will not make one. The benefits above are about tolerating treatment and avoiding a second cancer — which is exactly how NCCN and WHO frame them.
The regional question
What About Chewing Tobacco — Gutka, Khaini, Zarda and Paan Masala?
Nobody knows yet, and that is the honest answer. Smokeless tobacco drives most oral cavity cancer in India, but the trials behind immunotherapy in head and neck cancer were run where smoking dominated. No reliable evidence says a chewing history predicts response, better or worse. Treat any claim that it does with suspicion.
Smokeless tobacco is classified by IARC as carcinogenic to humans, and in Telangana and Andhra Pradesh it is the exposure behind most cancers of the tongue, cheek and gum. What has not been answered is whether tumours caused by chewing carry the same genetic fingerprint as tumours caused by smoking, and therefore whether the immune system engages with them in the same way. The research simply has not been done at the scale needed.
So the practical position is this. Your chewing history will not be used to predict your response, because it cannot be. It will still matter, for three reasons that have nothing to do with prediction: continuing keeps injuring the tissue your team is trying to heal, it makes mouth pain and ulcers harder to attribute, and the whole exposed lining stays at risk of a second, separate cancer even after the first one is treated.
This is not a lecture about a habit. It is a statement about what the evidence can and cannot tell you, so that nobody sells you a prediction that does not exist.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
A Tobacco History Does Not Close Any Door
Bring your reports. A medical oncologist will tell you plainly whether immunotherapy applies to your cancer, and what to do about tobacco alongside it.
Eligibility, stated plainly
Will You Be Refused Immunotherapy Because You Still Use Tobacco?
No. Tobacco use is not an eligibility criterion anywhere in checkpoint-inhibitor immunotherapy. Eligibility is decided by whether local treatment can still control the cancer, by PD-L1 testing on tumour tissue, by physical fitness and organ function, and by autoimmune disease or steroid dose. You will be asked to stop, and offered help, but nothing is withdrawn.
People hide current tobacco use from their oncologist far more often than teams admit, usually out of shame rather than dishonesty. It is worth naming the fear directly: nobody is going to take a treatment away from you because you answered truthfully. The table below is what the decision is actually made from.
| Factor | Does it decide whether immunotherapy is offered? |
|---|---|
| Whether surgery or radiation can still control the cancer | Yes. Local treatment that can still clear disease is considered before any systemic treatment. |
| PD-L1 expression on tumour tissue, reported as CPS | Yes. It can decide whether treatment is given alone, given with chemotherapy, or not used. |
| How well you are physically, day to day | Yes. If you are in bed for most of the day, the likely burden outweighs the likely benefit. |
| Active autoimmune disease on immune-suppressing medicine | Yes. Usually excluded, or considered only with specialist input. |
| A high daily steroid dose | Yes. Usually deferred while your team checks whether the dose can safely be reduced. |
| Smoking history, current smoking, or chewing tobacco | No. It changes the support you are offered, not whether you are offered treatment. |
| Age on its own | No. Fitness and organ function matter. The number does not. |
Smoking is also the largest modifiable risk factor for bladder and kidney cancer, where immunotherapy sits much further forward in the pathway than it does in oral cancer. If that is your diagnosis, immunotherapy for bladder cancer after BCG fails and immunotherapy plus targeted therapy for kidney cancer describe a very different set of options from the ones on this page.
The real risk tobacco adds
Does Tobacco Make Immunotherapy Side Effects Worse?
There is no reliable evidence that tobacco makes immune-related reactions more common. What it clearly does is make them harder to spot. Smoking-related lung damage produces the same cough and breathlessness as immune pneumonitis, which is treatment-caused lung inflammation needing urgent care. Report any new or worsening breathlessness the same day.
| What you notice | Why tobacco confuses it | What to do |
|---|---|---|
| New or worsening cough, breathlessness on activity you managed before | A COPD or emphysema flare and immune pneumonitis look almost identical from the outside | Call the helpline the same day. Breathlessness at rest means going to the emergency room now. |
| Mouth ulcers, soreness, difficulty eating | Tobacco-related mucosal damage and treatment-related soreness overlap completely | Report it at or before your next visit so it is examined rather than assumed. |
| Loose motions more often than usual, blood or mucus in stool | Nothing to do with tobacco — but often dismissed as diet by people already blaming themselves | Call the same day. Do not treat it at home as ordinary diarrhoea. |
| Chest pain, racing heartbeat, collapse, severe confusion | Easy to attribute to years of smoking rather than to the treatment | Go to the emergency room now. Tell the treating doctor you are on immunotherapy. |
If a new symptom appears between cycles, call before you wait:
Call the CION Helpline: 1800 202 8726Carry your immunotherapy card. Any doctor who sees you — a GP, a dentist, an emergency physician — needs to know you are on this treatment, because an immune-related reaction is managed differently from an infection.
Why the whole mouth is watched, not just the tumour
Long tobacco exposure changes the entire lining of the mouth, throat and food pipe, not only the patch where the first cancer appeared. That is why a second, separate primary cancer can arise in tissue that looked normal, and why follow-up examines the whole tract rather than the treated site alone. It is also the clearest reason cessation is treated as part of the plan rather than as a lifestyle footnote.
What to actually do
How Do You Stop When You Are Already on Treatment?
Tell your treating team first, then use the free national services. Ask your oncologist about nicotine replacement and craving medicines, which can be timed around infusion cycles. The Government of India National Tobacco Quitline is 1800-11-2356. A missed call to 011-22901701 starts the free mCessation text programme. Household support matters more than willpower.
- 1
Say it out loud to your team
Tell your medical oncologist exactly what you use and how much, including chewing. It changes how a cough, an ulcer or a scan finding is interpreted. It does not change what you are offered.
- 2
Ask about nicotine replacement and craving medicines
These exist, they are inexpensive, and they are managed alongside cancer treatment rather than instead of it. Ask your oncologist which is appropriate for you and when to start it, rather than buying something over the counter mid-cycle.
- 3
Use the free national services
The Government of India National Tobacco Quitline is 1800-11-2356, open through the day. A missed call to 011-22901701 enrols you in the free mCessation programme, which sends structured messages over several months. Both are free and both work in Indian languages.
- 4
Handle chewing differently from smoking
Substitution is where most people slip. Plain elaichi or saunf is a genuine substitute. Tobacco-free paan masala is not, because it usually still contains areca nut, which IARC also classifies as carcinogenic to humans.
- 5
Change the household, not just yourself
If a tin sits in the house, or a family member offers one out of habit, quitting during treatment is close to impossible. Tell the people you live with what you are doing and ask them to stop offering.
If you relapse, say so at the next visit. A relapse changes the support you need. It does not change your treatment plan, and it is not held against you.
Support, not judgement
Ask the Question You Have Been Avoiding
Every consultation here runs 45 minutes and covers what your tobacco history does and does not change about your options.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Tobacco and Immunotherapy: Your Questions Answered
Does smoking affect how well immunotherapy works?
It depends on the cancer. In non-small-cell lung cancer, tumours from people with a long smoking history tend to carry more genetic damage, and checkpoint-inhibitor treatment has generally worked better in current and former smokers than in people who never smoked. In head, neck and upper gastrointestinal cancers that pattern has not held consistently, and smoking status is not used to decide whether immunotherapy is given. NCCN and ESMO head and neck guidance uses PD-L1 expression, reported as a combined positive score, as the biomarker that changes the plan. A tobacco history is part of your story, but it is not the number your oncologist treats from.
Does quitting tobacco now help, even after immunotherapy has already started?
Yes, and it is worth doing at any point. Stopping tobacco after a cancer diagnosis is recommended by NCCN smoking cessation guidance and by WHO, because continuing is linked to more treatment complications, poorer wound and tissue healing, and a higher risk of a second tobacco-related cancer later. Quitting also removes one common source of cough and breathlessness, which makes it easier for your team to tell an ordinary smoker's cough apart from an immune-related lung reaction that needs treating urgently. Nobody expects you to manage it alone. Ask your oncologist about nicotine replacement and craving medicines, which are handled alongside cancer treatment rather than instead of it.
Does chewing tobacco such as gutka, khaini or zarda affect immunotherapy response?
Honestly, nobody knows yet. Smokeless tobacco is classified by IARC as carcinogenic to humans and it is the main driver of oral cavity cancer in India, but the trials that established immunotherapy in head and neck cancer were run largely in populations where smoking, not chewing, was the dominant exposure. There is no reliable evidence that a chewing history predicts how you will respond, in either direction. Anyone who tells you gutka use makes immunotherapy work better or worse is going past the evidence. What chewing does change is the practical picture: mouth ulcers, pain and difficulty eating are already common, and continuing keeps damaging the tissue your team is trying to heal.
Will I be refused immunotherapy because I still smoke or chew tobacco?
No. Tobacco use is not an eligibility criterion for checkpoint-inhibitor immunotherapy. Eligibility is decided by whether the cancer has returned or spread beyond what local treatment can control, by PD-L1 biomarker testing on tumour tissue, by how well you are physically, by organ function, and by whether you have an active autoimmune disease or take a high daily steroid dose. None of those is a tobacco question. Your team will still ask you to stop, and will offer help to do it, but that is support rather than a condition. Being honest about current use matters far more than the answer being the one you think is wanted.
Does tobacco make immunotherapy side effects worse?
There is no reliable evidence that tobacco makes immune-related reactions more common, but it does make them harder to read. Years of smoking often leave chronic lung damage such as COPD or emphysema. A flare of that can look almost identical to immune-related pneumonitis, which is inflammation of the lungs caused by the treatment and needs urgent assessment. Smoking-related mouth and throat changes similarly blur into treatment-related soreness. This does not rule immunotherapy out. It means any new or worsening cough, breathlessness or chest tightness is reported the same day rather than assumed to be the usual smoker's cough. Breathlessness at rest means going to the emergency room now.
Should I tell my oncologist if I am still using tobacco?
Yes, always, and being asked is not a test you can fail. Your team needs to know because current tobacco use changes how they interpret a cough, a mouth ulcer or a scan finding, and because it changes what support they offer you. Nothing is withdrawn because of the answer. If it helps, the Government of India National Tobacco Quitline is 1800-11-2356, and a missed call to 011-22901701 starts the free mCessation text programme. Telling the person treating you is more useful than either, because they can time cessation support around your infusion cycles.